Cephalon Loses Bid For Quick Win In Marketing Suit
By Sherry Mazzocchi · March 28, 2011, 7:50 PM EDT
Cephalon Inc. lost a summary judgment bid Wednesday in a Pennsylvania class action claiming the company marketed the cancer pain management drug Actiq for off-label uses and caused third-party payors to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login